ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2009
Efficient identification and evaluation of effective Helicobacter pylori therapies.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Is hybrid therapy more efficient in the eradication of Helicobacter pylori infection? A systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.World journal of gastroenterology · 2012Pooled it
- Trial
- High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections.Helicobacter · 2014Trial
- Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study.Journal of gastroenterology and hepatology · 2012Trial
- Trial
- Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.Journal of gastroenterology · 2010Trial
- Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2010Trial
- A Gut Signature of Microbiome, Bile Acid, and Quorum-Sensing Profiles Is Associated withMicroorganisms · 2026Article
- Tegoprazan-Amoxicillin Dual Therapy for Clarithromycin-ResistantMicroorganisms · 2025Article
- Tailored Therapy vs. Empirical Therapy forJournal of personalized medicine · 2025Review
- An Update on Eradication ofMiddle East journal of digestive diseases · 2024Review
- Efficacy and tolerability ofHealth science reports · 2024Article
- Curcumin clarithromycin nano-form a promising agent to fight Helicobacter pylori infections.World journal of microbiology & biotechnology · 2023Article
- Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023Review
- The prevalence and treatment outcomes ofJGH open : an open access journal of gastroenterology and hepatology · 2023Article
- A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites againstAntibiotics (Basel, Switzerland) · 2022Article
- Review
- Transitioning ofAntibiotics (Basel, Switzerland) · 2020Review
- Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection.The Korean journal of internal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Annually hundreds if not thousands of patients fail empiric H. pylori eradication therapy. Failure occurs in part because routine post treatment testing, which provides an early warning of increasing antibiotic resistance, is not universally done and physicians are generally unaware that cure rates with legacy triple therapy (a proton-pump inhibitor, amoxicillin, and clarithromycin) in most places has fallen below 80%. We propose first, institution of routine post eradication testing and second, abandonment of the "better than another therapy" approach to separating acceptable from unacceptable therapies. Instead, we propose using results-based outcomes (ie, >95% cure rates). H. pylori should be evaluated as other infectious diseases (ie, few would compare a new antibiotic for pneumonia with the previous best choice whose effectiveness was now impaired because of resistance). Randomized comparisons should be restricted to studies designed to improve (eg, simplify or reduce costs) high cure rate therapies while maintaining efficacy. We also discuss potential ethical issues such as those including known or suspected low cure rate therapies. Legacy therapies cannot be identified as "approved" or "recommended" even if both statements were true. Instead patients and ethics boards must receive "full disclosures" both before and during studies that include all that might affect a patient's decision to enter or to continue. Finally, we provides advice regarding trial design using "best shot" pilot studies to efficiently identify tentative effective regimens which are then confirmed in randomized trials all the while minimizing patient risks and drug exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.